The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
Abstract
Purpose: High levels of serum-soluble mesothelin family proteins (SMRP) have been found to be associated with malignant mesothelioma (MM), but not lung cancer (LC). To verify the clinical role of this marker for both these tumors, we tested serum SMRP in the largest population of thoracic cancers ever assembled. Experimental Design: SMRP blood concentrations were measured in 107 patients with MM, 215 patients with LC, 130 patients with benign respiratory diseases (BRD), and 262 controls. Statistical comparison between mean serum SMRP levels in all groups was done and receiver operating characteristic curves were constructed to evaluate the performance of this marker. Results: SMRP levels were significantly higher in patients with MM and LC than in patients with benign respiratory diseases and controls (P < 0.001). The area under the receiver operating characteristic curve for serum SMRP discriminating MM and controls was 0.77 (95% confidence interval, 0.71-0.83), with a best cutoff of 1.00 nmol/L (sensitivity, 68.2%; specificity, 80.5%). In both MM and LC, serum SMRP levels did not differ significantly between early and late stages. High SMRP levels proved to be an independent negative prognostic factor in patients with MM. Conclusions: Our data confirm that serum SMRP is a promising marker for the diagnosis, prognosis, and clinical monitoring of MM. We found that serum SMRP dosage may prove helpful in LC diagnosis as well. These data may also have positive repercussions on secondary preventive medical strategies for workers previously exposed to asbestos.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Cited by
Hooper, C., Lee, Y. C. G., Maskell, N., & on behalf of the BTS Pleural Guideline Group (2010) · Thorax · doi:10.1136/thx.2010.136978 · Cited by 824
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Chimeric antigen receptor T cells: a novel therapy for solid tumors
Yu, S., Li, A., Liu, Q., Li, T., Yuan, X., Han, X., & Wu, K. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0444-9 · Cited by 306
Diagnosis and Prognosis-Review of Biomarkers for Mesothelioma
Sun, H. H., Vaynblat, A., & Pass, H. I. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.60 · Cited by 55
Metadata
- Authors
- Cristaudo, A., Foddis, R., Vivaldi, A., Guglielmi, G., Dipalma, N., Filiberti, R., Neri, M., Ceppi, M., Paganuzzi, M., Ivaldi, G. P., Mencoboni, M., Canessa, P. A., Ambrosino, N., Chella, A., Mutti, L., & Puntoni, R.
- Venue
- Clinical Cancer Research
- Published
- 2007-09-01
- Volume
- 13
- Issue
- 17
- Pages
- 5076-5081
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2058959950
- Cited by
- 164
- References
- 1
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0629
- The paper
- Cristaudo, A., Foddis, R., Vivaldi, A., Guglielmi, G., Dipalma, N., Filiberti, R., Neri, M., Ceppi, M., Paganuzzi, M., Ivaldi, G. P., Mencoboni, M., Canessa, P. A., Ambrosino, N., Chella, A., Mutti, L., & Puntoni, R. (2007). Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0629
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.